(S)-tert-Butyl 1,4-oxazepan-6-ylcarbamate, 97%, 1g

Benzyl 2-hydroxybenzoate, 95.0%, 500g

4-ACETYL-2-FLUOROBENZONITRILE, 95.0%, 1g

(S)-4-Ethyl-4-hydroxy-11-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione, 95%, 250mg

Methyl 1-aminocyclopropanecarboxylate hydrochloride, 95.0%, 25g

(2-Fluoro-5-hydroxy-3-(trifluoromethyl)phenyl)boronic acid, 97%, 1g

1,4,7,10,13-Pentaoxa-16-azacyclooctadecane, 95.0%, 100mg

N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)aniline, 97%, 1g

2-((S)-N-(2,3-Dihydro-1H-inden-2-yl)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanamido)acetic acid hydrochloride, 97%, 100mg

Colonne capillaire GC ROTI®Cap-5, 10 m, 0,32 mm, 0,10 µm, 1 pièce(s)

1-(3-Bromophenyl)-1H-imidazole-4-carboxylic acid, 1g

di-tert-Butyl (2R,3R)-2,3-dihydroxysuccinate, 95%, 250mg

tert-Butyl 1,7-diazaspiro[3.5]nonane-1-carboxylate, 95.0%, 250mg